retatrutide weight loss injection Results:Trial Data and FDA Status New Drug Retatrutide Shows Benefits

Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health. The FDAs decision is largely based on data from the SELECT trial, which included more than 17,000 overweight or obese patients with a baseline age of 45 years old

They reduce stomach acid or prevent it from refluxing into the esophagus

Long-term studies confirmed sustained weight loss over two years, alongside reductions in the prevalence of prediabetes and cardiovascular risk factors (38)

They should be avoided in individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome

Access for DMV Residents : Serving patients in Silver Spring, Bethesda, Wheaton, Potomac, Falls Church, Tysons Corner, McLean, and beyond

GLP-1 Medications Explained: A Doctor's Guide to Effective Weight Loss [Tatosyan-Jones MD, Dr